Clinical trial · Interventional
Prostatic Artery Embolization Before Radical Prostatectomy in Prostate Cancer: A Proof-of-concept Study
NCT02917161CI-TRIAL-00028991completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
MRI findings after successful PAE in patients suffering from BPH suggest a complete necrosis of the prostate after this intervention. Thus, PAE might also play a role in the treatment of prostate cancer. This proof of concept study assess the impact of PAE in patients with proven prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Prostatic Artery Embolization (PAE) | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Prostatic Artery Embolization (PAE)
- description
- PAE is performed 6weeks before RALP
- interventionNames
- Device: Prostatic Artery Embolization (PAE)
Primary outcomes (1)
- measure
- Tumor response
- timeFrame
- 6 weeks after PAE (at the time of RALP)
- description
- Histological assessment of the excised prostate to determine whether pathological complete response was achieved, defined as complete absence of histologically identifiable cancer cells in the excised prostate.
Secondary outcomes (10)
- measure
- Histological Tumor Regression Grade
- timeFrame
- 6 weeks after PAE (at the time of RALP)
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 45 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Men 45 - 75 years old undergoing RALP * Patient has biopsy-proven prostate adenocarcinoma * Localized disease (tumorstage cT1-cT2), assessed by clinical and MRI findings * Written informed consent Exclusion Criteria: * Severe atherosclerosis * Severe tortuosity or ectasia in the aortic bifurcation or internal iliac arteries * Tumor stage \> cT2 assessed by clinical and MRI findings * Allergy to intravenous contrast media * Contraindication for MRI imaging * Renal failure (GFR\<60ml/min) * History of pelvic irradiation or radical pelvic surgery
References
Publications (0)
Data not yet available
No reference posted for this study.